Highlights of the second international conference on "Immunotherapy in Pediatric Oncology". - Wikidata - awgldk - TriplyDB

Highlights of the second international conference on "Immunotherapy in Pediatric Oncology".

Highlights of the second international conference on "Immunotherapy in Pediatric Oncology".

http://www.wikidata.org/entity/Q37919880

about

Declining childhood and adolescent cancer mortality Acute myelogenous leukemia stem cells: from Bench to Bedside.Highlights of the third International Conference on Immunotherapy in Pediatric Oncology.

P2860

Q34060045-F1683292-B6ED-4819-92FD-C0932C7CC106 Q38020081-87D83D6D-2DE4-446A-B61E-37A8212F2C95 Q39403785-539C835E-D591-418C-BC62-F50B026817B8

P2860

Highlights of the second international conference on "Immunotherapy in Pediatric Oncology".

http://www.wikidata.org/entity/Q37919880

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Highlights of the second inter ...... herapy in Pediatric Oncology".

@en

Highlights of the second inter ...... herapy in Pediatric Oncology".

@nl

type

label

Highlights of the second inter ...... herapy in Pediatric Oncology".

@en

Highlights of the second inter ...... herapy in Pediatric Oncology".

@nl

prefLabel

Highlights of the second inter ...... herapy in Pediatric Oncology".

@en

Highlights of the second inter ...... herapy in Pediatric Oncology".

@nl

P1433

Q37919880-94063453-97D6-448A-9046-44D6E7523E64

P1476

Q37919880-9F57DAD4-EBCD-4411-B9DE-247CC83AB2DD

P2093

Q37919880-38AEF58E-3212-490A-BE45-F2554504D42F

Q37919880-51287D31-3818-4B4A-87B5-E5C842C40DB8

Q37919880-7F74B468-42E9-41BA-B54E-516963FF5AC1

Q37919880-BA1A90AB-F3D3-480F-8A96-C3096769641E

Q37919880-C3368160-98D0-45C8-9505-709E03BE6F2D

Q37919880-C765E529-0B41-4959-ADFE-12FF7452EADD

P2860

Q37919880-09A24221-FA00-4671-8334-BF4304F0B7E0

Q37919880-0B57B919-E751-49A9-81BF-9C22C7D628E1

Q37919880-0DC2E112-866C-4D6A-8B97-2FAF440B3861

Q37919880-12A57BCD-8591-4A1E-BEDC-862613E7DA90

Q37919880-144D0353-EBCD-4671-86FC-5B4B4983BFAC

Q37919880-1B9C8393-CDCA-4D7E-A269-62629899577D

Q37919880-1F2CD654-6330-4275-BA60-5D622FAB489F

Q37919880-1F4C4DD7-98F5-450D-B107-8DA7233490FE

Q37919880-1F5173FA-293B-42E1-AF37-4A5B26C2C42C

Q37919880-29C696A7-2FEF-46F9-8BE7-A285BC2E2FBA

P304

Q37919880-A2CE1019-67F1-4ED9-A6ED-0342EFC596AA

P31

Q37919880-423182AC-8017-44AA-BEBB-0C4028AC38FB

P356

Q37919880-A522D894-C884-43DB-BA98-1C92B3E62CD8

P433

Q37919880-8DCF75D3-E8C8-4D54-9C77-8B5698C481C9

P478

Q37919880-600A39FC-C1E2-4EE8-9B04-99D983CF4DB1

P577

Q37919880-252DC5B6-2B11-4F05-BF21-E94A0B2BAEC1

P5875

Q37919880-51A7F0F7-EDB1-4FDB-B99D-2655D9D23CD3

P698

Q37919880-9FF6BF0D-A3B1-42C2-9EB0-8E80A861335A

P921

Q37919880-A124E2FA-AC9D-4266-85B5-8329F023E44C

P356

08880018.2011.596615

P1433

Pediatric Hematology and Oncology

P1476

Highlights of the second inter ...... herapy in Pediatric Oncology".

@en

P2093

Christian M Capitini

http://www.w3.org/2001/XMLSchema#string

Crystal L Mackall

http://www.w3.org/2001/XMLSchema#string

Laurence J N Cooper

http://www.w3.org/2001/XMLSchema#string

Malcolm Brenner

http://www.w3.org/2001/XMLSchema#string

Rupert Handgretinger

http://www.w3.org/2001/XMLSchema#string

Stephen Gottschalk

http://www.w3.org/2001/XMLSchema#string

P2860

Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

Cytotoxicity of activated natural killer cells against pediatric solid tumors.

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.

Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy.

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.

Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.

P304

459-460

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/08880018.2011.596615

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51583287

http://www.w3.org/2001/XMLSchema#string

P698

21854215

http://www.w3.org/2001/XMLSchema#string

P921